Karolinska Development - Interim report January - September, conference call Friday, November 25

STOCKHOLM - November 21, 2011. Karolinska Development will publish its interim
report for January - September 2011 at 08.30 CET on Friday, November 25. The
company will also host a conference call on the same day at 14.00 CET.

Participant access numbers: +46 (0)8 505 598 12, UK: +44 (0)20 710 862 05.

Hosts: Torbjörn Bjerke, CEO, and Gunnar Casserstedt, CFO.

For further information, please contact:
Benjamin Nordin, IR Director, Karolinska Development
Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com




TO THE EDITORS

About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class research into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP these to
the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out licensing of
products. This will result in upfront payments, milestone payments and
royalties.

An exclusive deal flow agreement with Karolinska Institutet Innovations AB,
along with other cooperation agreements with leading Nordic universities,
delivers a continuous flow of innovations.

Karolinska Development's flexible exit strategy enables projects to be exited at
whichever stage of development offers the greatest return on investment, usually
after Phase II clinical trials have indicated the desired pharmaceutical effect
on patients - this being an important value enhancing step.

Today, the portfolio consists of over 35 projects at various stages, from
concept development to Phase II clinical trials, twelve projects are in clinical
trials. The portfolio is particularly strong in the areas of cancer,
dermatology, inflammation, cardiovascular disease, women's health and diseases
that affect the central nervous system. For more information, see
www.karolinskadevelopment.com




[HUG#1565278]